ERBB2 and breast cancer: GQD (1:3) and m-GQD induced similar decreases in the viability of human epidermal growth factor receptor 2 (HER2)-positive breast cancer cells, showing 54.32% and 63.33% viabilities, respectively, after 72 h of treatment.